secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0000950170-25-077880
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics stockholders approve reverse stock split amendment at 2025 annual meeting
--------------------------------------------------------------------------------

- Reverse stock split amendment approved: 20,983,236 votes for, 3,224,611 against (86.9% of votes cast).
- Laura Berner and Brian O'Callaghan elected as Class I directors with 10.6M and 11.2M votes for, respectively.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2025: 23,330,316 votes for.
- Annual meeting had 24,362,318 shares represented out of 38,339,697 entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/0000950170-25-077880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017025077880/bolt-20250527.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-077880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer